Impressive !!! But not unexpected ..

@KCRS26 is shaping up to be another fantastic meeting for the #kidneycancer community. Great science, great conversations, and great people! Hope to see many of you in Boston on July 23–24, or online if you can’t make the trip. #KCRS26 will bring together leaders in kidney cancer research, clinical care, advocacy, industry, and the patient community. In-person attendance is limited due to space constraints; however, virtual registration is free and open to all. Register: bit.ly/KCRS26Registration #KidneyCancer @kidneycan

KCRS26 is shaping up to be another fantastic meeting for the #kidneycancer community. Great science, great conversations, and great people! Hope to see many of you in Boston on July 23–24, or online if you can’t make the trip. Register: bit.ly/KCRS26Registration #KCRS26 #KidneyCancer

Yes!

Join us !!

UNEQUIVOCALLY - IT DOES.

No doubt !!! Not my patient population, but this is such a devastating disease. Stunning result which will carry forward big time. Congrats to all the collaborators, industry and most importantly our patients who give their precious time to make breakthroughs possible

Join us at KCRS 2026. Free online. kcrs.kidneycan.org

The faculty lineup for #WorldGU26 continues to grow! Several more outstanding thought leaders have joined since our last announcement, and there’s still more to come. Check out the updated faculty roster, featuring conference chairs @CaPsurvivorship & @Daniel_J_George ow.ly/vvfG50YMUgU The 2-day CE-accredited conference returns to Nashville, TN, on December 3-5, 2026. Save the date and follow us for more faculty announcements and updates! Who are you most excited to hear from? @aaparicioMD @tingbao2011 @PBarataMD @katy_beckermann @mishabeltran @jackiebrown_MD @AlanBryce9 @drjefstathiou @MarkTFlemingMD1 @BGarmezy @OncHahn @MRHarrisonMD @EHeath4100 @EJonasch @MonikaJoshimd @jonathan_leeman @PavlosMsaouel @maughanonc @BradMcG04 @CParkMD @drphil_urology @EdwinPosadasMD @charlesryanmd @MutlaySayan @Scarps_kristen @cnsternberg @sonpavde @sandysrimd @alantanmd @DrKarineTawagi @drulkav @jeffyoriomd @bilenma @TDorffOnc @NaomiHaas5 @MikeLattanzi @MoningiShalini @ashleyrossmdphd @bsomer @HHammersMD @MattMilowsky

Triplets are an uphill battle if you choose a potent IO/TKI combo as the comparator. Nivo/Ipi is actually the doublet to beat for drug development. Cosmic 313 suffered from choosing the wrong TKI, Litespark 012 from its design. There is still room for triplets..

The #KidneyCancer Research Summit is truly a "Who's Who" of #RCC trailblazers. Register NOW to grab your free, front-row virtual seat for #KCRS26! Scheduled for July 23–24, 2026 in Boston, KCRS gathers global leaders across research, clinical care, and industry to share data, exchange ideas, and drive progress forward. Don't miss out! Secure your spot here: bit.ly/KCRS26Registration #AcceleratingCures Please share!📣 @DrChoueiri @HHammersMD @montypal @arihakimi @DrRanaMcKay @tompowles1 @KimrynRathmell @BraunMDPhD @BradMcG04 @AlbigesL @LisaHenske @VincentWenxinXu @JBrugarolas @WesleyYipMD @charlesbnguyen @DrYukselUrun @NazliDizman @ReneeSaliby @PavlosMsaouel @MikeSerzanMD @crisbergerot @AChakrabortyPhD @JudithVarner2 @AdanmaAnjiMD

Thank you for highlighting! Great session & discussion on advanced RCC therapies w/ Drs. @HHammersMD @JVentoMD @hannahdzmd

As #KidneyCancerAwarenessMonth comes to a close, the work continues. Throughout March, we’ve explored the facts, symptoms, treatment options, and research that are shaping the future of #KidneyCancer care. Awareness is an important first step — but progress depends on continued research, advocacy, and support for the kidney cancer community. Thank you for helping raise awareness, share knowledge, and support the work to #AccelerateCures for kidney cancer. #KnowledgeIsPower

@HHammersMD @CParkMD @mecmededucation #GUMaTOS

Wonderful effort! Please participate. trccproject.org/

Our friends and collaborators at High5Oncology were on the ground in San Francisco FIND THEM HERE 👉 buff.ly/9peFwD4 Capturing THE KEY discussions from ASCO GU and highlighting the innovations shaping the future of GU oncology and THEIR #GU26 PAGE IS NOW LIVE!! Tagging some of the amazing @high5md GU faculty @amerseburger @EfstathiouEleni @weoncologists @nachoduranm @GoebellJ @HHammersMD @IvanyiPhilipp @montypal @brian_rini @OncoBellmunt @scserendipity1 @GoebellJ @PGrivasMDPhD @IvanyiPhilipp @y_loriot @tompowles1 @bjartell @scserendipity1 @EfstathiouEleni @grimm_mo @amerseburger @declangmurphy @nealshore @OncoAlert #ProstateCancer #KidneyCancer #BladderCancer

We remember Peter Rooney, a dedicated KidneyCAN advocate whose curiosity, determination, and generosity helped strengthen the kidney cancer community. After his diagnosis, Peter made it his mission to learn everything he could about kidney cancer—asking thoughtful questions about the science, the research, and the treatments that could help patients in the future. That knowledge made him a powerful voice on Capitol Hill, where he worked tirelessly to advocate for research funding. Even while facing the physical challenges of metastatic disease, Peter continued to walk the halls of Congress during Advocacy Days, meeting with lawmakers and sharing the patient perspective. He approached this work with honesty about the realities of treatment and a steady optimism that made him both effective and inspiring. Peter’s advocacy was often a shared effort with his wife, Katharina, who stood beside him throughout the journey. Together they brought grace, purpose, and a deep commitment to helping others.

#ReedOn3! The McLaughlin family has launched an incredible grassroots fundraiser to support #KidneyCancer research. Inspired by Reed McLaughlin, a devoted father, husband, coach, and loyal supporter of everyone around him, the Reed on 3 campaign is bringing people together to raise awareness and funds for kidney cancer. Their goal is $50,000, and they’re already more than $22,000 of the way there! Help them reach their goal: bit.ly/ReedOn3 #AcceleratingCures

Comprehensive presentation by Dr. @HHammersMD spotlighting emerging targets in RCC: From HIF-2α inhibition to mRNA vaccines, CAR-T cells, and bispecific antibodies. The field is evolving fast, with so much on the horizon. #GU26 @OncoAlert @OncBrothers

Greetings from Day Two @ASCO #GU26, where @advocatekidneys is busy taking in the latest #KidneyCancer research and connecting with friends from around the globe. We're excited to see what is shared tomorrow on the latest in #rcc research!